News

Mezavant is claimed to be the first and only Health Canada approved once-daily oral formulation of mesalamine, and the first mesalamine to be approved by Health Canada for

The company says I2E 3.0 provides accessible text mining, enabling research and business decision-makers to uncover relevant insights by extracting key facts and relationships from document collections. According

Emend (fosaprepitant dimeglumine) for injection is approved for use in combination with other antiemetic medicines for the prevention of acute and delayed nausea and vomiting associated with initial

The FDA communicated a refusal to file, citing several issues including the adequacy of the analytical methodology to characterize the active pharmaceutical ingredient of Coprexa; a request to

The agreement, under the FDA’s special protocol assessment (SPA) process, affirms that the LibiGel Phase III clinical trial design, clinical endpoints, sample size, planned conduct and statistical analyses

Published online in Blood by the Burnham Institute’s president and CEO, John Reed and collaborators, the paper summarized study findings demonstrating that mice treated with apogossypol experienced less

Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism. ImaRx is continuing its stability program to evaluate the potential for further

Clexane is used to inhibit clot formation in venous and arterial vessels to prevent potential acute or chronic complications of venous or arterial thrombosis. The recommended dose regimen

The study findings demonstrate that mice treated with Apogossypol experienced less hepatotoxicity and gastrointestinal toxicity than those treated with Gossypol. The results support Coronado Biosciences’ continued development of